OncoCyte (OCX:TSX) Annual Reports & Investor Relations Material

Overview

OncoCyte Corporation, a leading molecular diagnostics company based in Irvine, California, is making waves in the detection of cancer. With a focus on research, development, and commercialization of proprietary laboratory-developed tests, OncoCyte is quickly gaining recognition for its cutting-edge technologies. Among its offerings are DetermaRx, a molecular test for early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression assay. The company also provides a range of other services, including biomarker discovery testing, assay design and development, biopharma, and clinical trial support services. Additionally, OncoCyte has engaged in a notable collaboration agreement with Life Technologies Corporation to develop and commercialize Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. Since its incorporation in 2009, this innovative company has been making significant strides in the fight against cancer both in the United States and abroad.

Frequently Asked Questions

What is OncoCyte's ticker?

OncoCyte's ticker is OCX

What exchange is OncoCyte traded on?

The company's shares trade on the TSX stock exchange

Where are OncoCyte's headquarters?

They are based in Toronto, Ontario

How many employees does OncoCyte have?

There are 51-200 employees working at OncoCyte

What is OncoCyte's website?

It is oncocyte.com

What type of industry is OncoCyte?

OncoCyte is in the Conglomerates industry

Who are OncoCyte's peers and competitors?

The following five companies are OncoCyte's industry peers:

- HGL Limited

- Ramsdens Holdings PLC

- Georgia Capital Plc

- Valmont Industries

- Seven Group Holdings Limited